Sai Life Sciences Limited (BSE: 544306, NSE: SAILIFE), a leading Indian Contract Research, Development and Manufacturing Organization (CRDMO), announced its financial results for the third quarter and nine months ended December 2025. The company delivered robust growth, driven by demand in CRO and CDMO services.<\/p>\n\n\n\n
Revenue from operations reached \u20b9556 crore in Q3 FY26, up 27% from \u20b9440 crore in Q3 FY25. This growth reflected strong contributions from both CRO and CDMO segments.<\/p>\n\n\n\n
EBITDA increased 54% to \u20b9191 crore from \u20b9124 crore year-over-year, with margins expanding 605 basis points to 34%. This improvement stemmed from higher capacity utilization, operational efficiencies, and cost optimization.<\/p>\n\n\n\n
Profit after tax (PAT) surged 86% to \u20b9100 crore, compared to \u20b954 crore in the prior-year quarter, highlighting enhanced profitability.<\/p>\n\n\n\n
For the nine months ended December 2025, revenue from operations grew 43% to \u20b91,590 crore from \u20b91,115 crore in 9M FY25. EBITDA rose 79% to \u20b9472 crore, while PAT more than tripled, up 199% to \u20b9245 crore from \u20b982 crore.<\/p>\n\n\n\n
These figures outperformed broader CRDMO industry trends, supported by sustained demand and volume growth across key service lines.<\/p>\n\n\n\n
Sai Life Sciences advanced its AI and digital platforms, applying AI-driven retrosynthetic analysis to machine learning-generated compounds for faster route design. The company delivered a full library of AI-designed macrocyclic peptides, showcasing AI’s role in complex modalities.<\/p>\n\n\n\n
Technology adoption included a centralized group for photochemistry and electrochemistry, alongside strengthened flow capabilities in discovery and CMC. Automation efforts featured a permeability measurement platform, high-throughput experimentation in India, and continuous counter-current LLE scaling.<\/p>\n\n\n\n
Capital expenditure totaled \u20b9405 crore as of the quarter-end, on track toward the FY26 plan of \u20b9700 crore, focusing on manufacturing and process development infrastructure.<\/p>\n\n\n\n
Quality remained a priority, with eight customer audits completed across units, yielding zero data integrity deviations or critical observations.<\/p>\n\n\n\n
The company released its 6th Sustainability Report 2024\u201325, detailing ESG progress. It earned My Green Lab (MGL) Green-level certification for four laboratories\u2014two PR&D and two Medicinal Chemistry\u2014with over 98% compliance.<\/p>\n\n\n\n
A joint case study with Bayer highlighted a hybrid solar-wind captive power model at the Bidar site via a long-term power purchase agreement.<\/p>\n\n\n\n
Krishna Kanumuri, Managing Director and CEO, stated that Q3 FY26 advanced the company’s science-led CRDMO positioning through AI, digital tools, and modern chemistry. Capacity expansions and talent additions align with client needs for complex programs.<\/p>\n\n\n\n
Siva Chittor, Chief Financial Officer, emphasized disciplined execution driving outperformance, with capex reinforcing scalable infrastructure. A solid order pipeline positions Sai Life Sciences for sustained profitable growth.<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Sai Life Sciences Limited (BSE: 544306, NSE: SAILIFE), a leading Indian Contract Research, Development and Manufacturing Organization (CRDMO), announced its financial results for the third quarter and nine months ended December 2025. The company delivered robust growth, driven by demand in CRO and CDMO services. Q3 FY26 Financial Performance Revenue from operations reached \u20b9556 crore […]<\/p>\n","protected":false},"author":2388,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392,5747,5],"tags":[8150,15853],"class_list":["post-179909","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","category-healthcare-stocks","category-latest","tag-life-sciences","tag-pharmaceutical-industry-india"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":177358,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q3-fy26-earnings-results\/","url_meta":{"origin":179909,"position":0},"title":"Laurus Labs Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 23, 2026","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Laurus Labs Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177750,"url":"https:\/\/alphastreet.com\/india\/innova-captab-limited-accelerating-strategic-growth-with-strong-q3-and-9-month-fy26-performance\/","url_meta":{"origin":179909,"position":1},"title":"Innova Captab Limited Accelerating Strategic Growth with Strong Q3 and 9-Month FY26 Performance","author":"Staff Correspondent","date":"January 26, 2026","format":false,"excerpt":"Innova Captab Limited (NSE: INNOVACAP\/BSE: 544067), is a leading integrated pharmaceutical company with a comprehensive business model spanning the entire value chain, including research and development, manufacturing, and marketing. The company serves as a preferred CDMO partner for prominent global pharmaceutical companies while maintaining a robust branded generics business in\u2026","rel":"","context":"In "LATEST"","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":178298,"url":"https:\/\/alphastreet.com\/india\/piramal-pharma-ltd-q3-fy-2026-financial-results-navigating-cyclical-headwinds-with-strategic-adjustments\/","url_meta":{"origin":179909,"position":2},"title":"Piramal Pharma Ltd Q3 FY 2026 Financial Results: Navigating Cyclical Headwinds with Strategic Adjustments","author":"Staff Correspondent","date":"January 29, 2026","format":false,"excerpt":"Piramal Pharma Ltd (NSE: PPLPHARMA), a leading global pharmaceutical and life sciences company headquartered in Mumbai, reported its financial results for the third quarter (Q3) of the fiscal year ending December 31, 2025, on January 29, 2026. The quarter\u2019s performance reflects a mix of operational challenges alongside areas of resilient\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/piramal.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/piramal.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/piramal.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/piramal.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":180266,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-aarti-pharmalabs-limited-reports-sequential-margin-recovery-in-q3-fy26-as-cdmo-transit-impact-weighs-on-revenue\/","url_meta":{"origin":179909,"position":3},"title":"Aarti Pharmalabs Limited reports sequential margin recovery in Q3 FY26 as CDMO transit impact weighs on revenue","author":"Staff Correspondent","date":"February 10, 2026","format":false,"excerpt":"Aarti Pharmalabs Limited (NSE: AARTIPHARM, BSE: 543748) reported a sequential improvement in operating performance in the quarter ended Dec. 31, 2025, as margins recovered quarter on quarter despite a year-on-year decline in revenue, according to the company\u2019s Q3 FY26 results presentation. Key Q3 FY26 highlights: Operational revenue stood at \u20b94,253\u2026","rel":"","context":"In "LATEST"","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":180863,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-akums-drugs-pharmaceuticals-reports-14-8-revenue-growth-in-q3-fy26-results\/","url_meta":{"origin":179909,"position":4},"title":"Earnings Summary – Akums Drugs & Pharmaceuticals Reports 14.8% Revenue Growth in Q3 FY26 Results","author":"Staff Correspondent","date":"February 15, 2026","format":false,"excerpt":"Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS), a pharmaceutical contract development and manufacturing organization (CDMO) announced its third-quarter and nine-month financial results for fiscal year 2026 on February 13, 2026. On the day results were released, the stock closed at \u20b9484.95, representing a one-day gain of \u20b933.60 or 7.44%. Quarterly\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":173653,"url":"https:\/\/alphastreet.com\/india\/syngene-q3-fy26-earnings-results\/","url_meta":{"origin":179909,"position":5},"title":"Syngene Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 22, 2026","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2388"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=179909"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179909\/revisions"}],"predecessor-version":[{"id":179910,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179909\/revisions\/179910"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=179909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=179909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=179909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}